Schizophrenia Clinical Trial
Official title:
Does Acute Oxytocin Administration Enhance Social Cognition in Individuals With Schizophrenia?
Individuals with schizophrenia have been found to have deficits in social cognition, which is defined as the functions that are engaged during social interactions. Social cognition has been found to be critical in predicting multiple aspects of community functioning. There are no currently available medications that have been consistently found to improve social cognition in individuals with schizophrenia. Oxytocin functions as a neurotransmitter that is thought to be involved in multiple aspects of social behavior and related emotions. In this study, we test the hypothesis that acute administration of intranasal oxytocin will improve social cognition in individuals with schizophrenia.
Schizophrenia is characterized by the presence of positive symptoms (delusions,
hallucinations, disorganization of thought process and behavior) as well as negative
symptoms (blunted affect, alogia, and avolition), neurocognitive deficits, and impaired
social cognition. While positive symptoms can often respond well to antipsychotic
medications, the latter symptoms are more difficult to treat. In this study, we will focus
on social cognition, which is defined as the functions that are engaged during social
interactions. Social cognition has been categorized into four main domains: theory of mind,
social perception, attributional bias, and emotional processing. Social cognition in
patients with schizophrenia has been found to be critical in predicting multiple aspects of
community functioning. There are currently two broad approaches to improve social cognition
in patients with schizophrenia: pharmacological and psychosocial interventions. While
psychosocial interventions (training exercises to target improvement in domains of social
cognition) have shown some benefit, their resultant improvements have been limited in their
distribution across multiple domains as well as their generalization to improved functioning
in the community. Pharmacological trials have yielded mixed results, and there are not any
currently available medications that have been consistently found to improve social
cognition in patients with schizophrenia2. One potential future therapeutic target for
enhancing social cognition is the oxytocin system.
Oxytocin is a nine-amino acid peptide that, in addition to its role in the periphery for
regulating lactation and uterine contractions, functions centrally as a neurotransmitter
which is involved in multiple aspects of social behavior and related emotions. Specifically,
it has been found to modulate emotion recognition, trust, eye contact, empathic accuracy, as
well as envy and gloating. Given oxytocin's role in social functioning, in conjunction with
the deficits in social functioning found frequently in individuals with schizophrenia, there
have been several studies over the past three decades examining the oxytocin system in
humans with schizophrenia and in rodent experimental models.
It has been found that individuals with schizophrenia do not show the same level of increase
in oxytocin as normal controls in response to trust-related interpersonal interactions, and
low plasma oxytocin predicted negative symptoms of schizophrenia. Additionally, it has also
been found that plasma oxytocin levels predicted the ability of patients with schizophrenia
to identify facial expressions. Finally, it has been found recently that sustained regular
administration of intranasal oxytocin significantly reduced both positive and negative
symptoms of schizophrenia. Thus, there is significant evidence supporting further research
studying the effect of oxytocin on social cognition. It is not yet known if exogenous
administration of oxytocin will have acute effects on neuropsychological measures of social
cognition in individuals with schizophrenia, and this is the focus of this proposed pilot
study.
The overall hypothesis guiding this study is that acute oxytocin administration will improve
social cognition (as assessed by a composite score comprising two measures of "low level"
social cognitive processes and two measures of "high level" social cognitive processes) in
individuals with schizophrenia. Our primary goals are to assess the feasibility of this
experimental paradigm and to generate pilot data and obtain estimates of effect sizes which
can be used in planning future larger studies.
;
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05039489 -
A Study on the Brain Mechanism of cTBS in Improving Medication-resistant Auditory Hallucinations in Schizophrenia
|
N/A | |
Completed |
NCT05321602 -
Study to Evaluate the PK Profiles of LY03010 in Patients With Schizophrenia or Schizoaffective Disorder
|
Phase 1 | |
Completed |
NCT05111548 -
Brain Stimulation and Cognitive Training - Efficacy
|
N/A | |
Completed |
NCT04503954 -
Efficacy of Chronic Disease Self-management Program in People With Schizophrenia
|
N/A | |
Completed |
NCT02831231 -
Pilot Study Comparing Effects of Xanomeline Alone to Xanomeline Plus Trospium
|
Phase 1 | |
Completed |
NCT05517460 -
The Efficacy of Auricular Acupressure on Improving Constipation Among Residents in Community Rehabilitation Center
|
N/A | |
Completed |
NCT03652974 -
Disturbance of Plasma Cytokine Parameters in Clozapine-Resistant Treatment-Refractory Schizophrenia (CTRS) and Their Association With Combination Therapy
|
Phase 4 | |
Recruiting |
NCT04012684 -
rTMS on Mismatch Negativity of Schizophrenia
|
N/A | |
Recruiting |
NCT04481217 -
Cognitive Factors Mediating the Relationship Between Childhood Trauma and Auditory Hallucinations in Schizophrenia
|
N/A | |
Completed |
NCT00212784 -
Efficacy and Safety of Asenapine Using an Active Control in Subjects With Schizophrenia or Schizoaffective Disorder (25517)(P05935)
|
Phase 3 | |
Completed |
NCT04092686 -
A Clinical Trial That Will Study the Efficacy and Safety of an Investigational Drug in Acutely Psychotic People With Schizophrenia
|
Phase 3 | |
Completed |
NCT01914393 -
Pediatric Open-Label Extension Study
|
Phase 3 | |
Recruiting |
NCT03790345 -
Vitamin B6 and B12 in the Treatment of Movement Disorders Induced by Antipsychotics
|
Phase 2/Phase 3 | |
Recruiting |
NCT05956327 -
Insight Into Hippocampal Neuroplasticity in Schizophrenia by Investigating Molecular Pathways During Physical Training
|
N/A | |
Terminated |
NCT03261817 -
A Controlled Study With Remote Web-based Adapted Physical Activity (e-APA) in Psychotic Disorders
|
N/A | |
Terminated |
NCT03209778 -
Involuntary Memories Investigation in Schizophrenia
|
N/A | |
Completed |
NCT02905604 -
Magnetic Stimulation of the Brain in Schizophrenia or Depression
|
N/A | |
Recruiting |
NCT05542212 -
Intra-cortical Inhibition and Cognitive Deficits in Schizophrenia
|
N/A | |
Completed |
NCT04411979 -
Effects of 12 Weeks Walking on Cognitive Function in Schizophrenia
|
N/A | |
Terminated |
NCT03220438 -
TMS Enhancement of Visual Plasticity in Schizophrenia
|
N/A |